DNMT3A and acute myeloid leukemia: Collectively, DNMT3A plays a dual role in AML CAR-T therapy: patient-derived DNMT3A mutations can indirectly reduce CAR-T efficacy through chronic T cell stimulation and exhaustion, whereas manipulation of DNMT3A within CAR-T cells themselves can preserve stem-like, functional phenotypes and improve therapeutic outcomes.